查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1963957

酵素結合免疫吸附 ）檢測法市場 - 全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年

Enzyme Linked Immunosorbent Assay Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球酵素結合免疫吸附檢測法(ELISA) 市場預計將從 2025 年的 37.9 億美元成長到 2031 年的 60.8 億美元，複合年成長率為 8.21%。

酵素連結免疫吸附試驗 (ELISA) 是一種廣泛應用的基於微孔板的分析技術，用於檢測和測量生物樣本中的可溶性物質，例如抗體、抗原、蛋白質和荷爾蒙。市場成長的主要驅動力是全球慢性疾病和感染疾病負擔的日益加重，這些疾病和感染需要頻繁且準確的診斷檢測才能有效管理。此外，這些檢測方法在藥物發現和開發過程中的廣泛應用也顯著推動了市場需求。根據國際糖尿病聯盟 (IDF) 預測，到 2024 年，全球將有約 5.89 億成年人患有糖尿病，凸顯了可靠的生物標記分析和持續健康監測解決方案的緊迫性。

市場概覽
預測期 2027-2031
市場規模：2025年 37.9億美元
市場規模：2031年 60.8億美元
複合年成長率：2026-2031年 8.21%
成長最快的細分市場 夾心ELISA
最大的市場 北美洲

然而，諸如聚合酵素鏈鎖反應(PCR) 和分子診斷等先進替代診斷技術的普及，憑藉其更高的靈敏度和更快的檢測速度，對該市場構成了重大挑戰。這些先進平台的激烈競爭可能會促使醫療機構優先考慮速度和準確性，從而限制傳統免疫檢測在某些高精度臨床領域的應用。

市場促進因素

慢性病和感染疾病的蔓延是全球酵素結合免疫吸附檢測法(ELISA) 市場的主要驅動力。這是因為 ELISA 被認為是識別特定抗體和抗原的黃金標準，需要嚴格的診斷通訊協定。感染疾病病原體帶來的沉重負擔使得頻繁檢測成為必要，以確保有效的疾病管理和控制。例如，世界衛生組織 (WHO) 於 2024 年 10 月發布的《2024 年世界結核病報告》估計，2023 年全球將有 1,080 萬人感染結核病，凸顯了準確進行傳染病篩檢的重要性。此外，慢性病也對市場需求產生了顯著影響。美國癌症協會於 2024 年 1 月發布的《2024 年癌症事實與數據》報告預測，2024 年美國新增癌症病例數將首次超過 200 萬例，這表明對使用成熟免疫檢測系統進行可靠的腫瘤標記分析的需求日益成長。

同時，生物製藥研發和藥物發現舉措的不斷拓展是市場成長的關鍵驅動力。製藥公司在整個藥物開發過程中高度依賴酵素連結免疫吸附試驗（ELISA），例如免疫抗原性測試、藥物動力學研究以及生物製藥的毒性篩檢。隨著業界專注於開發新型療法，對研發基礎設施的投資不斷增加，直接導致試劑和檢測試劑盒的消耗量上升。根據羅氏於2024年3月發布的《2023年度報告》，該集團的核心研發投資達到132億瑞士法郎，這筆巨額投資推動了對高精度生物分析儀器的需求。對藥物發現領域的持續資本投入確保了對高靈敏度診斷檢測的持續需求。

市場挑戰

全球酵素結合免疫吸附檢測法(ELISA) 市場擴張的主要障礙是來自先進診斷技術的日益激烈的競爭，尤其是聚合酵素鏈鎖反應(PCR) 和分子診斷技術。與傳統的基於微孔板的免疫檢測相比，這些替代系統能夠提供更快的檢測速度和更高的靈敏度。因此，在需要即時做出臨床決策和高精度檢測的情況下，例如基因分析和傳染病檢查，檢查室和醫療機構越來越傾向於採用這些先進方法。這一趨勢有效地阻礙了 ELISA 試劑盒在對準確性和速度要求極高的領域的應用，從而降低了其在高價值臨床市場中的潛在佔有率。

近期產業趨勢凸顯了競爭平台的湧現，也印證了這場技術變革的規模。根據美國臨床實驗室醫師協會 (ASCL) 統計，2024 年臨床實驗室博覽會吸引了約 900 家參展，清楚地表明了該行業正向自動化和先進分子技術轉型。商業性關注和創新集中於尖端替代技術，凸顯了市場動態。隨著醫療系統和製造商將資源集中於更靈敏、更快速的診斷工具，傳統酵素連結免疫檢測的需求持續承壓，阻礙了這一關鍵診斷領域的成長。

市場趨勢

自動化高通量ELISA工作站的日益普及正在改變檢查室的工作流程，以滿足對可重複性和操作效率的迫切需求。面對不斷成長的檢體量，生物分析檢查室和診斷中心正果斷地摒棄人工操作，轉向採用全整合機器人系統，從而降低人事費用和人為誤差。這種轉變在免疫診斷領域尤其顯著，自動化能夠在確保準確性的同時，快速處理複雜的檢測。根據Revvity於2025年2月發布的2024年度報告，該公司診斷業務收入達15.09億美元，其中免疫診斷業務收入成長4370萬美元，成為收入成長的關鍵驅動力，也顯示市場對先進自動化解決方案的強勁需求。

同時，由於傳統模擬方法難以檢測低濃度生物標記物，市場正加速向單分子檢測技術和超靈敏數位ELISA的轉型。這項技術創新使臨床醫生和研究人員能夠以飛克級定量蛋白質，為腫瘤學和神經病學等領域的疾病早期檢測創造了新的機會。隨著臨床療效的檢驗和普及程度的提高，向這些新一代平台的過渡正在加速。正如RTTNews在2025年11月報導的《Quanterix公司第三季虧損超出預期》所述，該公司宣布第三季營收達4,023萬美元，較去年同期成長12.3%，顯示數位生物標記檢測系統的商業性發展勢頭強勁。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：酵素結合免疫吸附檢測法的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（直接ELISA、間接ELISA、夾心ELISA）
    • 按應用領域（疾病診斷、疫苗研發等）
    • 依最終使用者（醫院、研究機構、學術機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美酵素結合免疫吸附檢測法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲酵素結合免疫吸附檢測法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區酵素結合免疫吸附市場檢測法

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲酵素結合免疫吸附市場檢測法

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲酵素結合免疫吸附市場檢測法

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球酵素結合免疫吸附檢測法：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories, Inc
  • Agilent Technologies, Inc
  • Merck KGaA
  • Promega Corporation
  • Neogen Corporation
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • BioMerieux SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24325

The Global Enzyme Linked Immunosorbent Assay Market is projected to expand from USD 3.79 Billion in 2025 to USD 6.08 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.21%. ELISA is a widely utilized plate-based analytical method designed to detect and measure soluble substances, including antibodies, antigens, proteins, and hormones, within biological samples. The market's growth is primarily fueled by the increasing global burden of chronic and infectious diseases, which demands frequent and precise diagnostic testing for effective management. Furthermore, the growing application of these assays in drug discovery and development processes significantly strengthens demand. According to the International Diabetes Federation, there were roughly 589 million adults living with diabetes globally in 2024, emphasizing the urgent need for dependable biomarker analysis and ongoing health monitoring solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.79 Billion
Market Size 2031USD 6.08 Billion
CAGR 2026-20318.21%
Fastest Growing SegmentSandwich ELISA
Largest MarketNorth America

However, the market faces a substantial obstacle regarding the availability of advanced alternative diagnostic technologies, such as polymerase chain reaction (PCR) and molecular diagnostics, which frequently provide superior sensitivity and more rapid turnaround times. The fierce competition presented by these sophisticated platforms potentially restricts the usage of traditional immunoassays within specific high-precision clinical sectors, as healthcare providers may favor newer methods for their speed and accuracy.

Market Driver

The escalating prevalence of chronic and infectious diseases acts as a major engine for the Global Enzyme Linked Immunosorbent Assay Market, necessitating rigorous diagnostic protocols where ELISA serves as the gold standard for identifying specific antibodies and antigens. The significant burden of infectious pathogens necessitates high testing volumes to ensure effective disease control and management. For instance, the World Health Organization's 'Global Tuberculosis Report 2024', released in October 2024, estimated that 10.8 million individuals contracted tuberculosis worldwide in 2023, underlining the vital need for precise infectious disease screening. Additionally, chronic diseases heavily influence market demand; the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024 projected that the United States would exceed 2 million new cancer cases for the first time in 2024, highlighting the increasing requirement for reliable tumor marker analysis via established immunoassay systems.

Concurrently, the broadening scope of biopharmaceutical R&D and drug discovery initiatives is a significant propeller of market growth. Pharmaceutical firms rely heavily on ELISA throughout the drug development pipeline for tasks such as immunogenicity testing, pharmacokinetic studies, and toxicity screening of biologics. As the industry sharpens its focus on developing novel therapeutics, investment in research infrastructure has escalated, leading to a direct rise in the consumption of reagents and assay kits. According to Roche's 'Annual Report 2023' published in March 2024, the group's core research and development investments climbed to CHF 13.2 billion, demonstrating the substantial financial commitment that fuels the demand for high-precision bioanalytical instruments. This sustained capital allocation towards discovery ensures a continuous requirement for sensitive diagnostic assays.

Market Challenge

The principal impediment to the expansion of the Global Enzyme Linked Immunosorbent Assay (ELISA) Market is the mounting competition from advanced diagnostic technologies, specifically polymerase chain reaction (PCR) and molecular diagnostics. These alternative systems provide faster turnaround times and enhanced sensitivity compared to conventional plate-based immunoassays. As a result, laboratories and healthcare providers are increasingly preferring these advanced methods for scenarios demanding immediate clinical decisions and high precision, such as genetic analysis and infectious disease testing. This trend effectively curtails the uptake of ELISA kits in sectors where accuracy and speed are critical, thereby reducing their potential share in high-value clinical markets.

The scale of this technological shift is evident in recent industry activities that emphasize these competing platforms. According to the Association for Diagnostics & Laboratory Medicine, the 2024 Clinical Lab Expo featured nearly 900 exhibitors, clearly highlighting the industry's transition toward automated and advanced molecular technologies. This aggregation of commercial focus and innovation on sophisticated alternatives accentuates the shifting market dynamics. As healthcare systems and manufacturers increasingly direct resources toward these more sensitive and rapid diagnostic tools, the demand for traditional enzyme-linked assays encounters persistent pressure, hindering their growth in vital diagnostic areas.

Market Trends

The increasing integration of automated high-throughput ELISA workstations is transforming laboratory workflows by meeting the urgent need for reproducibility and operational efficiency. Facing rising sample volumes, bioanalytical laboratories and diagnostic centers are decisively moving away from manual plate handling in favor of fully integrated robotic systems that reduce labor costs and human error. This shift is especially prominent in the immunodiagnostics field, where automation facilitates the swift processing of complex assays while maintaining precision. According to Revvity's 'Annual Report for Fiscal Year 2024' from February 2025, the company reported diagnostics segment revenue of $1,500.9 million, bolstered significantly by a $43.7 million rise in immunodiagnostics revenue, signaling strong demand for advanced automated solutions.

At the same time, the market is undergoing a major shift toward single-molecule detection technologies and ultrasensitive digital ELISA, spurred by the need to detect low-abundance biomarkers that conventional analog methods miss. This technological advancement enables clinicians and researchers to quantify proteins at femtogram levels, creating new opportunities for early disease detection in fields like oncology and neurology. The transition to these next-generation platforms is gaining speed as they become more clinically validated and accessible. As noted by RTTNews in November 2025 regarding the 'Quanterix Corp Q3 Loss Increases, Misses Estimates' report, Quanterix announced a 12.3% year-over-year revenue increase to $40.23 million for the third quarter, highlighting the increasing commercial momentum of its digital biomarker detection systems.

Key Market Players

  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories, Inc
  • Agilent Technologies, Inc
  • Merck KGaA
  • Promega Corporation
  • Neogen Corporation
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • BioMerieux SA

Report Scope

In this report, the Global Enzyme Linked Immunosorbent Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Enzyme Linked Immunosorbent Assay Market, By Type

  • Direct ELISA
  • Indirect ELISA
  • Sandwich ELISA

Enzyme Linked Immunosorbent Assay Market, By Application

  • Disease diagnosis
  • Vaccine Development
  • Other

Enzyme Linked Immunosorbent Assay Market, By End User

  • Hospitals
  • Research & Academic Institutions

Enzyme Linked Immunosorbent Assay Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Enzyme Linked Immunosorbent Assay Market.

Available Customizations:

Global Enzyme Linked Immunosorbent Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Enzyme Linked Immunosorbent Assay Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Direct ELISA, Indirect ELISA, Sandwich ELISA)
    • 5.2.2. By Application (Disease diagnosis, Vaccine Development, Other)
    • 5.2.3. By End User (Hospitals, Research & Academic Institutions)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Enzyme Linked Immunosorbent Assay Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Enzyme Linked Immunosorbent Assay Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Enzyme Linked Immunosorbent Assay Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Enzyme Linked Immunosorbent Assay Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Enzyme Linked Immunosorbent Assay Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Enzyme Linked Immunosorbent Assay Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Enzyme Linked Immunosorbent Assay Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Enzyme Linked Immunosorbent Assay Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Enzyme Linked Immunosorbent Assay Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Enzyme Linked Immunosorbent Assay Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Enzyme Linked Immunosorbent Assay Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Enzyme Linked Immunosorbent Assay Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Enzyme Linked Immunosorbent Assay Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Enzyme Linked Immunosorbent Assay Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Enzyme Linked Immunosorbent Assay Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Enzyme Linked Immunosorbent Assay Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Enzyme Linked Immunosorbent Assay Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Rad Laboratories, Inc
  • 15.3. Agilent Technologies, Inc
  • 15.4. Merck KGaA
  • 15.5. Promega Corporation
  • 15.6. Neogen Corporation
  • 15.7. F. Hoffmann-La Roche Ltd
  • 15.8. Siemens Healthineers AG
  • 15.9. Becton, Dickinson and Company
  • 15.10. BioMerieux SA

16. Strategic Recommendations

17. About Us & Disclaimer